Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novartis Ag ADR
(NY:
NVS
)
97.36
+2.24 (+2.35%)
Streaming Delayed Price
Updated: 1:44 PM EDT, Apr 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,382,717
Open
98.74
Bid (Size)
97.35 (2)
Ask (Size)
97.36 (1)
Prev. Close
95.12
Today's Range
97.13 - 99.50
52wk Range
92.19 - 108.78
Shares Outstanding
N/A
Dividend Yield
3.56%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
NVS Stock Earnings: Novartis Beats EPS, Beats Revenue for Q1 2024
Today 12:53 EDT
NVS stock results show that Novartis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Novartis Ag (NVS) Q1 2024 Earnings Call Transcript
Today 11:15 EDT
NVS earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Performance
YTD
-3.60%
-3.60%
1 Month
+1.70%
+1.70%
3 Month
-10.24%
-10.24%
6 Month
+2.82%
+2.82%
1 Year
-3.21%
-3.21%
More News
Read More
Novartis Extends Three-Day Stock Sprint With First-Quarter Beat And Raise
Today 8:52 EDT
Via
Investor's Business Daily
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Today 8:25 EDT
Via
Benzinga
Wall Street Set To Open Higher As Tesla Kicks Off 'Magnificent 7' Earnings: Why This Analyst Thinks Market Weakness Is A 'Healthy Pullback'
Today 6:55 EDT
Via
Benzinga
Topics
Bonds
Exposures
Debt Markets
Looking At Novartis's Recent Unusual Options Activity
April 11, 2024
Via
Benzinga
Top Analyst Reports For Novartis, American Express & ConocoPhillips
April 22, 2024
Via
Talk Markets
The Bad News Heading Into AbbVie's First-Quarter Earnings Report
April 19, 2024
Via
Investor's Business Daily
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
April 19, 2024
Via
Benzinga
Exposures
Product Safety
Novartis Multiple Sclerosis Drug Kesimpta Shows Substantial Benefit Of Up To 6 Years
April 17, 2024
Via
Benzinga
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
April 17, 2024
Via
The Motley Fool
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
April 21, 2024
Via
Benzinga
Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades
April 16, 2024
Via
Benzinga
Looking for an Easy Way to Earn Passive Income? This Vanguard ETF Pays a Dividend Yield of Nearly 4.9%.
April 14, 2024
Via
The Motley Fool
Topics
ETFs
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
April 11, 2024
Via
Benzinga
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Via
Investor's Business Daily
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
April 11, 2024
From
Arvinas Inc.
Via
GlobeNewswire
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
April 10, 2024
Via
Benzinga
SOUN Stock Alert: The $150 Million Reason SoundHound AI Is Down Today
April 10, 2024
Via
InvestorPlace
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Jack Ma Is Giving Alibaba (BABA) Stock a Big Boost
April 10, 2024
Via
InvestorPlace
Novartis Layoffs 2024: What to Know About the Latest NVS Job Cuts
April 10, 2024
Via
InvestorPlace
Topics
Workforce
Exposures
Layoff
Enliven Therapeutics Well-Positioned, With Conservative Trading Levels-Analyst Says
April 09, 2024
Via
Benzinga
Novartis To Axe 680 Development Jobs Amid Global Reshuffle: Report
April 09, 2024
Via
Benzinga
Johnson & Johnson's Carvykti Stands Ahead Of Bristol Myers' Rival Blood Cancer Therapy With FDA Approval For Wider Population
April 08, 2024
Via
Benzinga
Exposures
Product Safety
Why Is Novartis Stock Trading Higher On Thursday?
April 04, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.